<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>AZ US news feed</title>
    <link>http://www.astrazeneca-us.com/</link>
    <description>AstraZeneca is one of the world's leading pharmaceutical companies, our business is focused on turning good ideas into innovative, effective medicines that  make a real difference in important areas of healthcare. Use of the  AstraZeneca RSS Feed service and your right to receive this feed and any messages and/or content provided by way of this feed is subject to the Terms of Use as can be found at  http://www.astrazeneca-us.com/content/astrazeneca_usage_guidelines.asp.  You should check this link for updates from time to time. This RSS feed contains press releases and investor news.</description>
    <item>
      <title>AstraZeneca and the Philadelphia Department of Public Health provide free medicines to Pennsylvania’s uninsured</title>
      <link>http://www.astrazeneca-us.com/?itemId=7516204</link>
      <description>Learn how, with this program, AstraZeneca builds on its more than 30-year history of helping patients afford the medicines they need.</description>
      <pubDate>Fri, 20 Nov 2009 15:25:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7516204</guid>
      <dc:date>2009-11-20T15:25:00Z</dc:date>
    </item>
    <item>
      <title>AstraZeneca submits US New Drug Application for ticagrelor (BRILINTA™), an investigational antiplatelet agent</title>
      <link>http://www.astrazeneca-us.com/?itemId=7470811</link>
      <description>Visit the AstraZeneca U.S. Corporate Web site (www.astrazeneca-us.com) for more information.</description>
      <pubDate>Thu, 19 Nov 2009 07:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7470811</guid>
      <dc:date>2009-11-19T07:00:00Z</dc:date>
    </item>
    <item>
      <title>Results from two Phase II trials add to understanding of ticagrelor (BRILINTA™) and how it works in the body</title>
      <link>http://www.astrazeneca-us.com/?itemId=7470663</link>
      <description>View the ticagrelor data presented at the American Heart Association Scientific Session.</description>
      <pubDate>Wed, 18 Nov 2009 14:15:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7470663</guid>
      <dc:date>2009-11-18T14:15:00Z</dc:date>
    </item>
    <item>
      <title>CRESTOR® reduced risk of cardiovascular events in women by nearly half in new analysis of JUPITER study</title>
      <link>http://www.astrazeneca-us.com/?itemId=7470964</link>
      <description>Learn about two additional sub-population analyses from JUPITER also presented at American Heart Association annual meeting.</description>
      <pubDate>Tue, 17 Nov 2009 21:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7470964</guid>
      <dc:date>2009-11-17T21:00:00Z</dc:date>
    </item>
    <item>
      <title>Ticagrelor (BRILINTA™) demonstrated greater efficacy over clopidogrel in the most urgent clinical setting: Patients with ST-Segment Elevation Myocardial Infarction and planned Percutaneous Coronary Intervention (PCI)</title>
      <link>http://www.astrazeneca-us.com/?itemId=7470428</link>
      <description>See the late breaking data from PLATO sub-analysis presented at the American Heart Association Scientific Sessions.</description>
      <pubDate>Sun, 15 Nov 2009 13:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7470428</guid>
      <dc:date>2009-11-15T13:00:00Z</dc:date>
    </item>
    <item>
      <title>Actress Debi Mazar talks about her family’s experience with bipolar depression</title>
      <link>http://www.astrazeneca-us.com/?itemId=7423117</link>
      <description>Learn how actress shares her inspirational story as part of campaign to educate people about bipolar disorder.</description>
      <pubDate>Wed, 11 Nov 2009 17:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7423117</guid>
      <dc:date>2009-11-11T17:00:00Z</dc:date>
    </item>
    <item>
      <title>New post-hoc, pooled analysis shows SYMBICORT® improved airflow obstruction in patients with COPD</title>
      <link>http://www.astrazeneca-us.com/?itemId=7392247</link>
      <description>Learn how data also finds SYMBICORT achieved improvement in lung function within five minutes.</description>
      <pubDate>Mon, 09 Nov 2009 13:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7392247</guid>
      <dc:date>2009-11-09T13:00:00Z</dc:date>
    </item>
    <item>
      <title>AstraZeneca PLC third quarter and nine months results 2009</title>
      <link>http://www.astrazeneca-us.com/?itemId=7322185</link>
      <description>View full details of the event on our international site, and download the narrative and figures.</description>
      <pubDate>Thu, 29 Oct 2009 11:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7322185</guid>
      <dc:date>2009-10-29T11:00:00Z</dc:date>
    </item>
    <item>
      <title>Patients taking VIMOVO showed improved UGI tolerability assessments as compared to EC naproxen</title>
      <link>http://www.astrazeneca-us.com/?itemId=7317604</link>
      <description>Read about new results from two Phase III clinical trials shared at American College of Gastroenterology 2009 Annual Scientific Meeting in San Diego.</description>
      <pubDate>Wed, 28 Oct 2009 11:05:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7317604</guid>
      <dc:date>2009-10-28T11:05:00Z</dc:date>
    </item>
    <item>
      <title>Phase 2 data from oral NKTR-118 presented at American College of Gastroenterology in San Diego</title>
      <link>http://www.astrazeneca-us.com/?itemId=7315595</link>
      <description>Learn about new approach to treat opioid-induced constipation.</description>
      <pubDate>Tue, 27 Oct 2009 16:30:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7315595</guid>
      <dc:date>2009-10-27T16:30:00Z</dc:date>
    </item>
    <item>
      <title>AstraZeneca partners with Mercy Primary Care Center to help Michigan uninsured</title>
      <link>http://www.astrazeneca-us.com/?itemId=7287499</link>
      <description>Learn how AstraZeneca will provide free medication to Mercy Primary Care Center in Detroit under one of the company’s prescription savings programs.</description>
      <pubDate>Mon, 26 Oct 2009 13:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7287499</guid>
      <dc:date>2009-10-26T13:00:00Z</dc:date>
    </item>
    <item>
      <title>Patients taking VIMOVO™ showed a decrease in incidence of NSAID-associated ulcers</title>
      <link>http://www.astrazeneca-us.com/?itemId=7230779</link>
      <description>View results from PN400-301/302 studies presented at American College of Rheumatology Annual Scientific Meeting.</description>
      <pubDate>Mon, 19 Oct 2009 13:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7230779</guid>
      <dc:date>2009-10-19T13:00:00Z</dc:date>
    </item>
    <item>
      <title>U.S. Food and Drug Administration approves CRESTOR® for use in pediatric patients with heterozygous familial hypercholesterolemia</title>
      <link>http://www.astrazeneca-us.com/?itemId=7208516</link>
      <description>Read how the FDA decision was based on a supplemental New Drug Application submitted by AstraZeneca which included data from the PLUTO study.</description>
      <pubDate>Fri, 16 Oct 2009 12:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7208516</guid>
      <dc:date>2009-10-16T12:00:00Z</dc:date>
    </item>
    <item>
      <title>US Court of Appeals affirms Summary Judgment decision in SEROQUEL® patent litigation</title>
      <link>http://www.astrazeneca-us.com/?itemId=7063413</link>
      <description>Visit the AstraZeneca U.S. Corporate Web site (www.astrazeneca-us.com) for more information.</description>
      <pubDate>Fri, 25 Sep 2009 19:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7063413</guid>
      <dc:date>2009-09-25T19:00:00Z</dc:date>
    </item>
    <item>
      <title>Ticagrelor reduced cardiovascular deaths and heart attacks in ACS patients undergoing heart procedures: New data from PLATO trial</title>
      <link>http://www.astrazeneca-us.com/?itemId=7055388</link>
      <description>Significant effects shown with no increase in major bleeding compared to clopidogrel in head-to-head trial.</description>
      <pubDate>Thu, 24 Sep 2009 19:10:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7055388</guid>
      <dc:date>2009-09-24T19:10:00Z</dc:date>
    </item>
    <item>
      <title>AstraZeneca among Working Mother Magazine’s 2009 “Best Companies”</title>
      <link>http://www.astrazeneca-us.com/?itemId=7040614</link>
      <description>Read how this award acknowledges AstraZeneca’s commitment to family-friendly policies that support employee retention, employee engagement, and career advancement.</description>
      <pubDate>Tue, 22 Sep 2009 15:15:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7040614</guid>
      <dc:date>2009-09-22T15:15:00Z</dc:date>
    </item>
    <item>
      <title>AstraZeneca accepts Secretary Of Defense Award for supporting employees serving in National Guard and Reserve</title>
      <link>http://www.astrazeneca-us.com/?itemId=7027518</link>
      <description>Learn how this award is the highest recognition given by the U.S. government to employers for their outstanding support of employees who serve in the National Guard and Reserve.</description>
      <pubDate>Thu, 17 Sep 2009 21:30:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7027518</guid>
      <dc:date>2009-09-17T21:30:00Z</dc:date>
    </item>
    <item>
      <title>AstraZeneca wins 2009 EPA Mid-Atlantic Region Environmental Achievement Award</title>
      <link>http://www.astrazeneca-us.com/?itemId=7013907</link>
      <description>Visit the AstraZeneca U.S. Corporate Web site (www.astrazeneca-us.com) for more information.</description>
      <pubDate>Wed, 16 Sep 2009 13:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=7013907</guid>
      <dc:date>2009-09-16T13:00:00Z</dc:date>
    </item>
    <item>
      <title>New UD program promotes better exercise, nutrition and sleep</title>
      <link>http://www.astrazeneca-us.com/?itemId=6923993</link>
      <description>Learn about Healthy HENS program, developed with support from AstraZeneca, designed to help students eat right, exercise and get enough sleep.</description>
      <pubDate>Fri, 04 Sep 2009 11:45:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=6923993</guid>
      <dc:date>2009-09-04T11:45:00Z</dc:date>
    </item>
    <item>
      <title>AstraZeneca encourages all Americans to get their cholesterol checked during National Cholesterol Education Month in September</title>
      <link>http://www.astrazeneca-us.com/?itemId=6889818</link>
      <description>Learn how talking with a physician is a key step in setting, achieving, and maintaining a targeted cholesterol goal.</description>
      <pubDate>Tue, 01 Sep 2009 12:00:00 GMT</pubDate>
      <guid>http://www.astrazeneca-us.com/?itemId=6889818</guid>
      <dc:date>2009-09-01T12:00:00Z</dc:date>
    </item>
  </channel>
</rss>


